Pharmaceutical companies, much like grocery shoppers, are prone to making expensive, panic-driven mistakes when facing patent cliffs with empty pipelines. This "shopping hungry" phenomenon has historically led to large acquisitions that often fail to deliver positive shareholder returns, such as Bristol-Myers Squibb's $74 billion acquisition of Celgene in 2019. The current trend among pharmaceutical chiefs is to make frequent, smaller trips to the store, meaning a steady stream of small to medium-sized bets rather than one gigantic deal.
Investors have soured on the strategy of large acquisitions, perceiving them as creating significant integration risks without necessarily improving long-term growth. The industry has increasingly favored "bolt-on" deals, typically under $3 billion, with roughly two dozen such deals occurring annually over the past decade. This pace has accelerated in recent years, with 24 deals already recorded in 2026. This shift creates a climate of innovation, benefiting smaller and mid-sized biotech companies and cycling capital back into the ecosystem.
Examples of more disciplined buying include Novartis, which made an early bet with its approximately $2 billion acquisition in 2018 for the platform that yielded Pluvicto, a prostate-cancer drug now projected to achieve roughly $4 billion in annual sales. Merck, despite facing a patent cliff for its cancer drug Keytruda, which generated $31.7 billion last year and loses protection in 2028, has opted for a series of targeted assets rather than a single overwhelming acquisition. These include the 2021 $11.5 billion acquisition of Acceleron and the $11 billion buyout of Prometheus in 2023. Merck's shares are up more than 60% in the past 12 months, showcasing investor approval of this strategy. Through April 7, 19 deals valued at $1 billion or more have been announced this year, with none exceeding $10 billion, signaling a clear preference for spreading bets.
Big Pharma's continued need to acquire innovative drugs is driven by nearly half of the $700 billion in annual revenue from the 14 largest drug companies facing patent expiration by 2031. They also possess substantial financial capacity, with over $650 billion in "comfortable" M&A firepower. However, they are not overpaying; the median price paid in these deals has fallen to about seven times a target company’s projected revenue, down from approximately 11 times between 2007 and 2023. This indicates a disciplined, not frothy, market where the best environment for biotech is characterized by a high volume of smaller deals rather than a few massive ones.
